TB-500 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-11. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Middle ear and inner ear (barotitis or aerotitis) Paranasal sinuses (causing aerosinusitis) Lungs may be affected by both under-pressure or, more commonly, overpressure relative to the external pressure Eyes (the under-pressure air space is inside the diving mask or swimming goggles) Skin (when wearing a diving suit which creates an air space) Brain and cranium (temporal lobe injury secondary to temporal bone rupture) Teeth (causing barodontalgia, i.e., barometric pressure related dental pain, or dental fractures) Genital squeeze and associated urinary complications of P-valve use Intestinal barotrauma is caused by over-expansion of gas trapped in the intestines during ascent.
=== Electromagnetic flux === In radio astronomy, the unit of electromagnetic flux is the jansky (symbol Jy), equivalent to 10−26 watts per square metre per hertz (= 10−26 kg/s2 in base units, about 8.8×10−31 BTU/ft2). It is named after the pioneering radio astronomer Karl Jansky. The brightest natural radio sources have flux densities of the order of one to one hundred jansky.
=== International action: Stockholm Convention === PFOA was proposed for listing under the Stockholm Convention on Persistent Organic Pollutants in 2015, and on May 10, 2019, PFOA, its salts, and PFOA-related compounds were added to Annex A of the Stockholm Convention by the Conference of the Parties. Several hundred salts and precursors of PFOA fall within the scope of the restriction. A few specific exemptions remained. Among them is a time-bound exemption for PFOA in fire-fighting foam.
The biological value of proteins in general, hence also of grain-proteins, is fundamentally determined by the ratio between the essential amino acids to be found in cereals and the requirement of essential amino acids of the living creature, consuming protein...the most important way of raising the biological value ... [is] given by the technique of complementing. In 2011 PLOS ONE published an article investigating the specifics of protein combining for 1251 plant-based foods. The bases of reference are the amino acids indispensable to human nutrition, and the ideal proportioning of these amino acids in a meal. They explain, "complementation involves consuming two or more foods together to yield an amino acid pattern that is better than the sum of the two foods alone." In contrast to pairings based on food groups, such as pairing a grain with a bean, the investigators reported that pairing by food group was not supported by their work: "Examining the top 100 pairings for each food, we found no consistent pattern of food group-food group pairings."
== Early life == Michael Heseltine was born at Eaton Crescent, in Swansea in Wales on 21 March 1933. He was the son of Territorial Army Colonel Rupert Dibdin Heseltine (1902–1957), TD, of the Royal Engineers during the Second World War, a factory owner and South Wales local director of Dawnays Ltd, bridge and structural engineers, and Eileen Ray (née Pridmore). The Heseltine family were in the tea trade: Michael Heseltine's great-grandfather, William Heseltine, was a clerk who worked his way up to being manager of Tetley, later being involved in establishing a chain of grocers; he killed himself after suffering the loss of his fortune through debt and bad investments. Michael Heseltine's grandfather, John William Dibdin Heseltine (whose mother was a great-granddaughter of the composer and songwriter Charles Dibdin), became a tea salesman and relocated from Huntingdonshire to Swansea, the docks being a major arrival point for tea shipments. Earlier generations had been farm labourers in Pembrey. Heseltine's mother originated in West Wales, daughter of James Pridmore, a dock labourer who unloaded coal from ships, later hiring others to do so and founding West Glamorgan Collieries Ltd, a short-lived company that briefly worked two small mines on the outskirts of Swansea (1919–1921); his father, also James, worked at the Swansea docks. Due to this heritage Heseltine was later made an honorary member of the Swansea Dockers Club. Heseltine was brought up in relative luxury at No. 1, Eaton Crescent, Swansea (now No. 5).
Sources: en.wikipedia.org
=== Diseases === The moth is susceptible to viral diseases including nucleopolyhedrovirus (NPV). This is a naturally occurring virus whose natural hosts include Lepidoptera, arthropods, and Hymenoptera. From the family Baculoviridae, it is a type of Alphabaculovirus and its genome is 80–180kb long. NPVs are commonly used as pesticides for the cabbage looper. There are numerous NPVs, many of which were isolated from the cabbage looper or the alfalfa looper. NPVs vary in infectivity and virulence. For example, the AcMNPV isolates are more infectious than the TnSNPV (the SNPV/single nuclear polyhedrosis virus specific to the cabbage looper) isolates in the first instar, while the TnSNPV isolates produced more occlusion bodies, protein structures that protect the virus and increase long term infectivity. TnSNPVs are their most lethal during the third and fourth instars; they have detrimental effects such as delayed development, reduced egg production, and fewer hatched eggs. These effects are significantly diminished when the larvae are infected during the fifth instar, suggesting that the earlier infection is more effective. Bacillus thuringiensis (Bt) is a gram-positive soil bacterium from the phylum Bacillota. It is often used as a biological insecticide for numerous insect pests, including the cabbage looper, and reduces both growth rate and pupal weight. The cabbage looper has demonstrated resistance to Bt, specifically the toxin Cry1Ac, due to an autosomal recessive allele.
The tetrahydrofuran ring is found in diverse natural products including lignans, acetogenins, and polyketide natural products. Diverse methodology has been developed for the synthesis of substituted THFs.
Narrated by actress Nicola Duffett, directed by Gary Johnstone, produced by Paul Wilmshurst 18 September Coral Grief, 50 million years ago, northern Italy was under water; David Bellwood of James Cook University; David Barnes of the Australian Institute of Marine Science; biologist Garry Russ; the Florida Reef and Craig Quirolo; a 1970 episode of Four Corners (Australian TV program); Peter Moran and Sea star wasting disease; Peter Isdale and Bette Willis; biologist Angel Alcala of Silliman University, who was Secretary of Environment and Natural Resources from 1992–95; Peter Harrison of the National Marine Science Centre, Australia; geochemist Michael Gagan of the Australian National University.
== Class B peptidomimetics == This class of peptidomimetics encompasses peptides with a large number of non-natural amino acids, major backbone modifications or larger non-natural building fragments that resemble the conformation of a particular peptide binding motif. Examples involve D-peptide and peptidic foldamers such as beta-peptides.
== Research == Multiple studies have shown that LDN has promise as a treatment for chronic pain, some autoimmune disorders, and cancers. Studies on the efficacy of LDN for multiple sclerosis have been inconclusive. Clinical trials for its use as treatment of fibromyalgia were initiated in 2021. LDN is also being studied in long COVID. A 2018 therapeutic utilization review concluded that LDN may be an appropriate option for treatment of fibromyalgia and irritable bowel syndrome, but that "proper clinical trials are needed in order to establish evidence that could lead to correct indications, mode of administration, and other aspects necessary for effective clinical pharmacology of [low-dose naltrexone]." The UK's National Health Service echoed this sentiment in 2020. In a 2013 paper published in Arthritis & Rheumatology, authors Jarred Younger and Sean Mackey reported reduced circulating pro‑inflammatory cytokines and self‑reported pain in fibromyalgia patients using LDN. A 2018 review summarized mixed trial outcomes and emphasized methodological limitations. A 2023 systematic review published in the Australian Journal of General Practice found that preliminary research into the use of LDN as a treatment for fibromyalgia is promising. All clinical studies examined showed statistically significant improvements in pain and pain tolerance with mild side effects; however, sample sizes were small and the evidence is inconclusive.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.